Recent Trends in Prescription Drug Costs
Recent Trends in Prescription Drug Costs_JAMA 040516 Download View JAMA infographic
View the Latest: Prescription Drugs
Filter
-
-
Visualizing Health Policy: Recent Trends in Prescription Drug Costs
News ReleaseThis Visualizing Health Policy infographic spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices. Prescription drug spending rose sharply in 2014, driven by growth in expenditures on specialty drugs, including medications to treat cancer and hepatitis C. Medicare’s spending on prescription pharmaceuticals also has risen, largely due to the addition of the Medicare prescription drug benefit in 2006: between 2004 and 2014, the program’s share of US drug expenditures increased from…
-
Poll: Nearly Half of Adults Would Be Interested in Prescription Weight-Loss Drugs, But Enthusiasm Fades Based on Lack of Coverage and Risk of Regaining Weight
News ReleaseNearly half (45%) of the public are at least somewhat interested in taking a prescription weight-loss drug, including many who say they only want to lose a little weight, though many people lose interest when presented with potential financial and medical drawbacks, the latest KFF Health Tracking Poll reveals.The poll gauges the public’s interest in using prescription drugs to lose weight as a relatively new class of drugs, initially approved to treat diabetes, is garnering…
-
How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices?
Issue BriefA class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment. A new analysis compares list prices for semaglutide—including Ozempic, which has been approved in the U.S. for diabetes, and Wegovy, which has the same active ingredient and has been approved for weight…
-
Will Where You Live Determine Access and Coverage of Emerging Anti-Obesity Drugs?
Policy WatchThe U.S. Midwest and South regions have higher average obesity rates among adults. What does this mean for access and coverage of prescription drugs for weight loss?
-
How Medicare’s New Drug Price Negotiation Program Could Expand Access to Selected Drugs
Issue BriefThis brief examines how Part D enrollees’ access to and utilization of the first set of 10 selected drugs could be affected by the new Part D coverage and formulary requirements for selected drugs established by the Inflation Reduction Act and in CMS guidance, as well as the potential for lower out-of-pocket costs.
-
Florida’s Plan to Import Prescription Drugs from Canada, the First of its Kind, May Face Obstacles that Could Delay Implementation and Savings
News ReleaseA new KFF policy watch explains some of the hurdles the state of Florida still must clear before it can implement its novel plan to make some prescription drugs more affordable by importing them from Canada. Florida’s plan represents the first time the Food and Drug Administration (FDA) has granted authority for a state to safely import prescription drugs from another country. However, the state must take some additional steps to move forward with the…
-
What Are the Implications of the Recent Elimination of the Medicaid Prescription Drug Rebate Cap?
Policy WatchThis policy watch explains the Medicaid prescription drug rebate cap, examines how many drugs might be impacted, and explores the implications of recent manufacturer responses for Medicaid programs and enrollees.
-
Year in Review: 10 Health Policy Issues for 2023
Fact SheetThis fact sheet offers a look back at 10 issues that KFF tracked closely during 2023 in its polling, policy analysis and journalism, including summaries of major findings and news stories.
-
What Are the Current Costs and Outcomes Related to Mental Health and Substance Abuse Disorders?
FeatureMental health and substance use disorders, including addiction to opioids, are the leading cause of disease burden in the United States, and the U.S. has the highest mortality rate for these disorders among similarly wealthy countries. This slideshow explores the prevalence, outcomes, access to care, and costs of mental health disorders and substance abuse in the United States.